RTOG Foundation Studies


The RTOG Foundation Study Pages are accessible to participating institutions via a username and password. For further information regarding participation on a specific trial send an email to RTOGINFO@acr.org and include the name of the trial in your email.  


RTOG Foundation FAQs


RTOG Foundation Study 3501 - TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study Of Lapatinib (Tykerb®) For Non-HPV Locally Advanced Head And Neck Cancer With Concurrent Chemoradiation

RTOG Foundation Study 3502 - POSTILV: A Randomized Phase II Trial In Patients With Operable Stage I Non-Small Cell Lung Cancer: Radical Resection Versus Ablative Stereotactic Radiotherapy

RTOG Foundation Study 3503 - Phase II Trial of Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma

RTOG Foundation Study 3504  - Safety Evaluations of Nivolumab (Anti-PD-1) Added to Chemortherapy (CRT) Platforms in Patients with Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma 

RTOG Foundation Study 3505 - Randomized, Double Blinded Phase III Trial of Cisplatin and Etoposide plus Thoracic Radiation Therapy Followed By Nivolumab/Placebo for Locally Advanced Non-Small Cell Lung Cancer

RTOG Foundation Study 3506STEEL: A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with Post-Prostatectomy PSA Recurrences with Aggressive Disease Features

RTOG Foundation Study 3507KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA®) Plus Stereotactic Re-irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma

RTOG Foundation Study 3508 - A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance 1)

RTOG Foundation Studies 3509 and 3510 - Pragmatic Phase III Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation:  A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial

RTOG Foundation Study 3515 -  A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)

RTOG Foundation Data Monitoring Committee (DMC)

RTOG Foundation Non Study Specific Regulatory Documents

RTOG Foundation Non Study Specific Forms

RTOG Foundation Non Study Specific Templates